Fri. Aug 19th, 2022
Alport Syndrome Market

DelveInsight’s “Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the seven major markets (7MM) (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The report also covers provides insights into the emerging drugs, current treatment practices, market share of the individual therapies, market drivers, barriers, unmet medical needs, current and forecasted market size from 2019 to 2032 segmented by 7MM. 

Chronic Kidney Disease Disease Overview

Chronic kidney disease (CKD) is a syndrome where there are persistent alterations in kidney structure, function, or both with implications on the health of the individual. Examples of structural abnormalities include cysts, tumors, malformations and atrophy, which are evident on imaging. By contrast, kidney dysfunction can manifest as hypertension, edema, changes in output or quality of urine and growth delay in children. These changes are most often recognized by increased serum levels of creatinine, cystatin C, or blood urea nitrogen. Moreover, the most common pathological manifestation of CKD, regardless of the initiating insult or disease, is some form of renal fibrosis.

Several aspects need to be considered when managing patients with CKD, including controlling further nephron injury, normalizing single-nephron hyperfiltration, controlling CKD-related complications and preparing the patient for kidney replacement therapy. At the core of these is the principle of ‘the earlier, the better’—an effort to reduce the progression to ESRD and optimize renal outcomes.

Chronic Kidney Disease Market Key Facts

  • The total prevalent population of Chronic Kidney Disease (CKD) in the 7MM was 65,988,800+ in 2017. Estimates show the highest prevalent population of Chronic Kidney Disease (CKD) is in the United States, with 37,809,500+ cases in 2017.
  • As per the study by NIDDK, the overall prevalence of CKD increased from 12% to 14% between 1988 and 1994 and from 1999 to 2004, but has remained relatively stable since 2004.
  • Among the 7MM, the most prevalent cases of Chronic Kidney Disease (CKD) were recorded in the United States.
  • Among the European 5 countries, Germany had the highest prevalent population of Chronic Kidney Disease (CKD), followed by France and the United Kingdom. On the other hand, Spain had the lowest prevalent population of CKD in 2017.

Chronic Kidney Disease Market

The Chronic Kidney Disease (CKD) market size is anticipated to increase owing to the rising prevalent population of Chronic Kidney Disease (CKD) patients in the 7MM, along with the expected entry of premium price asset such Anti-inflammatories, Prolyl hydroxylase and IL-6 inhibitors.

The market outlook section of the report helps to understand the historic, current, and forecasted Chronic Kidney Disease market size by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology. 

The report gives a thorough detail of key trends, ongoing developments, and growth opportunities of each marketed and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders in the domain. 

Get the PDF Sample of the Report @

Chronic Kidney Disease Epidemiology

The epidemiology section covers insights into the historical and current Chronic Kidney Disease patient pool and forecasted trends for every seven major markets from 2019 to 2032. 

It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Discover more about the epidemiological segmentation @

Chronic Kidney Disease Drugs Uptake and Key Market Players

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Kidney Disease market or expected to get launched in the market during the study period. The analysis covers the drug uptake; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Chronic Kidney Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent development such as collaborations, acquisitions, and mergers, licensing patent details, and other information.

Chronic Kidney Disease Therapeutics Analysis

Some of the key companies in the Chronic Kidney Disease Market include:

  • GlaxoSmithKline
  • Akebia Therapeutics
  • FibroGen
  • Astellas Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Astra Zeneca
  • Tricida
  • Reata Pharmaceuticals
  • Corvidia Therapeutics

And many others.

Chronic Kidney Disease Therapies covered in the report include:

  • Daprodustat
  • Vadadustat
  • Roxadustat
  • Empagliflozin
  • Dapagliflozin
  • Veverimer
  • Bardoxolone Methyl
  • Ziltivekimab

And many others.

Get More Detailed Insights into the Emerging Therapies & Key Companies:-

Table of Content

  1. Key Insights
  2. Executive Summary 
  3. Chronic Kidney Disease Competitive Intelligence Analysis
  4. Chronic Kidney Disease Market Overview at a Glance
  5. Chronic Kidney Disease Disease Background and Overview
  6. Chronic Kidney Disease Patient Journey
  7. Chronic Kidney Disease Epidemiology and Patient Population
  8. Chronic Kidney Disease Treatment Algorithm, Current Treatment, and Medical Practices
  9. Chronic Kidney Disease Unmet Needs
  10. Key Endpoints of Chronic Kidney Disease Treatment
  11. Chronic Kidney Disease Marketed Products
  12. Chronic Kidney Disease Emerging Therapies
  13. Chronic Kidney Disease Seven Major Market Analysis
  14. Attribute Analysis
  15. Chronic Kidney Disease Market Outlook (7 major markets)
  16. Chronic Kidney Disease Access and Reimbursement Overview
  17. KOL Views on the Chronic Kidney Disease Market.
  18. Chronic Kidney Disease Market Drivers
  19. Chronic Kidney Disease Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:-

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Contact Info:
Shruti Thakur
Assistant Manager, Marketing & IB
Phone No: +91-9650213330
Email: [email protected]
Connect With Us: LinkedIn | Facebook | Twitter
For Latest Update: Healthcare Blog
Request for Sample Copy of the Report at:


Latest Reports By DelveInsight:

Chronic Kidney Disease Epidemiology Forecast

“Chronic Kidney Disease Epidemiology Forecast” report delivers an in-depth understanding of the historical, and forecasted epidemiology of Chronic Kidney Disease.

Chronic Kidney Disease (CKD) Pipeline Insights

“Chronic Kidney Disease (CKD) Pipeline Insights” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Chronic Kidney Disease market.

Other Trending Healthcare Reports by DelveInsight

By krehani

Leave a Reply

Your email address will not be published. Required fields are marked *